DPP-4 inhibitor
Vildagliptin
Brand names: Galvus
Adult dose
Dose: 50mg PO BD (or 50mg OD if eGFR <50)
Route: PO
Frequency: BD
Dose adjustments
Renal
50mg OD if eGFR <50
Clinical pearls
- T2DM combination therapy
- LFT monitoring required (every 3 months in 1st year)
Contraindications
- Type 1 DM
- DKA
- Hepatic impairment (any)
- Hypersensitivity
Side effects
- Hepatotoxicity
- Pancreatitis
- Hypoglycaemia (with sulfonylurea/insulin)
- Skin lesions
Interactions
- Insulin/sulfonylureas (hypoglycaemia)
Monitoring
- HbA1c
- LFTs
- Renal function
Reference: BNF; NICE NG28; https://bnf.nice.org.uk/drugs/vildagliptin/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
Pathways
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016